Selinexor

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

What's the purpose of the trial?

This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide.

Trial status

Accepting patients

Phase

Phase 2

Enrollment

Last Updated

4 months ago

Am I Eligible

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Carfilzomib
Daratumumab
Dexamethasone
Pomalidomide
Selinexor

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Carfilzomib-containing Regimen

Accepting patients

Pomalidomide-containing Regimen

Accepting patients

Daratumumab-containing Regimen

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.